Aditxt (ADTX) announced that its acquisition target, Evofem Biosciences (EVFM), has secured voting agreements with certain of its investors to ensure they will vote in favor of the merger proposal at Evofem’s upcoming Special Meeting of Stockholders.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADTX:
- Aditxt, Inc. Focuses on Growth Amid Nasdaq Compliance
- Aditxt announces ‘positive’ FDA feedback for Appili Therapeutics ATI-1801
- Appili Therapeutics announces FDA alignment on ATI-1801 NDA requirements
- Aditxt Enters Major Investment Agreement with Evofem
- Aditxt CEO Clarifies NASDAQ Compliance and Capital Strategy